Introduction A major driver of the global autologous cell therapy market is the rising demand for personalized and precision-based medical trea ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

We report the results of autologous CD133+ stem cell implantation in nine cases of critical limb ischemia being considered for amputation. As PAD occurs in an elderly patient population with high ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The study, published in Nature, opens new avenues for treating some genetic blood disorders without the need for stem cell transplantation or chemotherapy. SR-Tiget is internationally recognized ...

Our study addresses this challenge by resolving the heterogeneity of human stem cell–derived islet organoids and introducing a functional marker to isolate transplant-ready islets," said Dr.

Now, Chinese biotechnology company XellSmart has the potential to change this forever, as its allogeneic induced pluripotent stem cells (iPSC) regenerative therapy has been given the green light ...